NCT03229083Completed
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 21 (actual)
- First submitted
- 18 Jul 2017
- Start date
- 24 Jul 2019
- Primary completion date
- 14 Feb 2025
- Lead sponsor
- University of Rochester
- Diseases
- Kidney cancer
- NCT number
- NCT03229083
What you commit to
- Study type: Interventional
- Participants enrolled: 21
- From 24 Jul 2019 to the primary completion date, 14 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who were on the study previously will not be allowed to re-enroll in the event of a treatment change
Other illness
- Unable to come to the Wilmot Cancer Center for appointments every 3-4 months for routine visits with their primary oncologist
Other
- Women cannot be breast-feeding
- Does not have regular access to the internet
Who the study is looking for
- Diagnosis of histologically confirmed renal cell carcinoma of any subtype with either pathological or radiographic evidence of metastatic disease
- Greater than 18 years of age
- A participating Wilmot Cancer Center oncologist has determined that candidate should be started on either oral targeted therapy or immunotherapy for treatment of their advanced RCC; this can be for first-line or any subsequent line therapy
- Able to provide written informed consent
- Proficient in the English language and self-reports as literate
- Must have an active email address or access to a smart device on which text messages can be received
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Rochester Wilmot Cancer Institute Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.